30.1 Influenza, COVID-19 & Viral Respiratory Syndromes

Influenza: Virology, Clinical Features & Diagnostic Assessment

Influenza is an acute respiratory infection caused by negative-sense, single-stranded RNA viruses of the family Orthomyxoviridae. Annual epidemics cause substantial morbidity and mortality, particularly among extremes of age and individuals with chronic medical comorbidities.

Virology & Pathophysiology

• Influenza A: Infects humans and animal reservoirs (aquatic birds, swine). Characterized by two major surface glycoproteins: Hemagglutinin (HA), which binds sialic acid receptors on respiratory epithelial cells to facilitate viral entry, and Neuraminidase (NA), which enzymatically cleaves terminal sialic acid to release newly formed virions from infected host cells. Influenza A undergoes both antigenic drift (minor point mutations in HA and NA leading to seasonal epidemics) and antigenic shift (genetic reassortment between animal and human strains, creating novel surface antigens and pandemic potential).
• Influenza B: Infects humans almost exclusively and is categorized into two lineages (B/Yamagata and B/Victoria). Influenza B undergoes antigenic drift only, causing seasonal outbreaks but never pandemics.
• Incubation & Transmission: The incubation period averages 2 days (range 1 to 4 days). Transmission occurs via respiratory droplet aerosolization (coughing, sneezing) and fomites. Viral shedding commences 24 to 48 hours prior to symptom onset, peaks during the initial 48 to 72 hours of illness, and abates by 5 to 7 days in immunocompetent adults. Prolonged viral shedding (>10 to 14 days) occurs in young children, elderly adults, and immunocompromised hosts.

Clinical Presentation

• Classic Adult Presentation: Abrupt, explosive onset of systemic and respiratory symptoms ("patients can pinpoint the exact hour they became ill"). Hallmark manifestations include:
  • High fever (typically 38.5°C to 40.0°C / 101°F to 104°F) accompanied by shaking chills and rigors;
  • Severe, debilitating diffuse myalgias and arthralgias, prominent in the paraspinal and lower extremity musculature;
  • Retro-orbital or frontal headache, photophobia, profound prostration, and anorexia;
  • Non-productive dry cough, substernal burning or chest soreness, sore throat, and clear rhinorrhea.
• Physical Examination: Flushed facies, warm diaphoresis, hyperemic pharynx without purulent exudates, and mild cervical lymphadenopathy. Pulmonary auscultation is usually normal or reveals scattered dry rhonchi and mild wheezes. Focal crackles or signs of consolidation suggest pneumonia.
• Atypical Presentation in Older Adults: Adults aged ≥65 years frequently present without classic high fevers or prominent respiratory signs. Instead, influenza often manifests as acute delirium, confusion, lethargy, anorexia, unexplained falls, or acute decompensation of underlying congestive heart failure or COPD.

---

Diagnostic Modalities: Molecular NAAT vs. Rapid Antigen Tests

[!IMPORTANT] Clinical Decision Rule During Peak Epidemics: When influenza is actively circulating in the community, the presence of abrupt fever and cough in an adult has a positive predictive value exceeding 80%. Empiric antiviral therapy should be initiated immediately in patients with high-risk conditions without delaying for laboratory confirmation, and a negative rapid antigen test should not deter clinical treatment.

---

Antiviral Pharmacotherapy: Formulations, Timing & High-Risk Indications

Antiviral agents reduce the duration of fever and systemic symptoms by 24 to 36 hours, accelerate functional recovery, and decrease the incidence of secondary complications (acute otitis media, lower respiratory tract infection, hospitalization, and antibiotic exposure).

                         INFLUENZA ANTIVIRAL THERAPY

                     Confirmed or High-Suspicion Influenza
                                       │
            ┌──────────────────────────┴──────────────────────────┐
            ▼                                                     ▼
    Onset <=48 Hours                                      Onset >48 Hours
            │                                                     │
            │                                         Assess Risk Criteria:
            │                                         • Hospitalized / Severe illness
            │                                         • Age <2 or >=65 years
            │                                         • Chronic pulmonary / cardiac disease
            │                                         • Diabetes / CKD / Cirrhosis
            │                                         • Immunocompromised / Cancer
            │                                         • Pregnancy / <=2 wk postpartum
            │                                         • BMI >=40 kg/m²
            │                                         • Nursing home resident
            │                                                     │
            ├─────────────────────────────────────────────────────┤
            │                                                     │
            ▼                                                     ▼
   ANTIVIRAL INDICATED                                   ANTIVIRAL INDICATED
   • Oseltamivir 75 mg PO BID x 5d (preferred)          (If ANY high-risk criterion met)
   • Baloxavir single weight-based dose                 ─────────────────────────────────
   • Zanamivir 10 mg INH BID (no asthma/COPD)           If Healthy Host with Onset >48h:
   • Peramivir 600 mg IV single dose                    • Antiviral NOT indicated
                                                        • Symptomatic care only

Antiviral Drug Classes & Dosing Regimens

1. Neuraminidase Inhibitors (NAIs)

• Oral Oseltamivir (Tamiflu):
  • Adult Dosing: 75 mg PO twice daily for 5 days.
  • Renal Impairment Adjustments:
    • eGFR >60 mL/min: 75 mg PO BID;
    • eGFR 30 to 60 mL/min: 30 mg PO BID;
    • eGFR 10 to 30 mL/min: 30 mg PO once daily;
    • End-stage renal disease on hemodialysis: 30 mg PO immediately after each dialysis session.
  • Pregnancy & Lactation: Oseltamivir is the first-line drug of choice across all trimesters of pregnancy and during the first 2 weeks postpartum. Maternal physiologic benefits significantly outweigh potential drug risks.
  • Adverse Effects: Transient nausea (10%) and vomiting (8%), which are markedly alleviated by taking medication with meals. Rare neuropsychiatric events (confusion, hallucinations, delirium) have been reported, primarily in pediatric populations in East Asia.
• Inhaled Zanamivir (Relenza):
  • Adult Dosing: 10 mg (two 5-mg inhalations via Diskhaler) twice daily for 5 days. Approved for age ≥7 years.
  • CRITICAL CONTRAINDICATION: Absolutely contraindicated in individuals with underlying reactive airway disease, including asthma, COPD, or bronchiectasis, due to the life-threatening risk of precipitating acute bronchospasm and severe bronchoconstriction.
• Intravenous Peramivir (Rapivab):
  • Adult Dosing: Single IV infusion of 600 mg over 15 to 30 minutes. Approved for age ≥6 months.
  • Indication: Acute uncomplicated influenza in patients who cannot tolerate oral or inhaled routes (e.g., severe refractory emesis, malabsorption syndromes, or altered gastrointestinal motility).

2. Cap-Dependent Endonuclease Inhibitor

• Oral Baloxavir Marboxil (Xofluza):
  • Mechanism of Action: Selectively inhibits the cap-dependent endonuclease within the viral RNA polymerase complex, arresting viral mRNA synthesis. Demonstrates significantly faster reduction in viral load and viral shedding compared to oseltamivir.
  • Adult Dosing: Single oral dose administered once:
    • Weight 40 kg to <80 kg: Single 40-mg dose.
    • Weight ≥80 kg: Single 80-mg dose.
  • Drug Absorption Warning: Chelation occurs when co-administered with polyvalent cations; do not administer simultaneously with dairy products, calcium-fortified beverages, antacids (aluminum, magnesium), iron supplements, or sucralfate.
  • Contraindications & Limitations: Not recommended in pregnancy or lactation (inadequate safety profile); avoid in severely immunocompromised patients due to rapid selection for treatment-emergent resistance mutations (I38T/M/F).

The 48-Hour Clinical Rule & High-Risk Exceptions

• The Golden Window: Antiviral initiation within 48 hours of symptom onset provides maximal reduction in fever duration, symptom burden, hospitalizations, and secondary bacterial complications.
• Mandatory Indications for Antiviral Therapy REGARDLESS of Symptom Duration (>48 Hours):
  1. Hospitalized Patients: Any patient with suspected or confirmed influenza requiring acute hospitalization.
  2. Severe or Progressive Illness: Any outpatient demonstrating clinical deterioration, severe respiratory distress, hypoxemia (SpO2 <94%), or systemic toxicity.
  3. High-Risk Populations (CDC & IDSA Guidelines):
     • Children aged <2 years (highest hospitalization rates in infants <6 months);
     • Adults aged ≥65 years;
     • Individuals with chronic pulmonary disorders (asthma, COPD, bronchiectasis, cystic fibrosis, interstitial lung disease);
     • Individuals with chronic cardiovascular disorders (congestive heart failure, coronary artery disease, cardiomyopathy; excluding isolated hypertension);
     • Chronic renal disease (CKD stage 3-5, ESRD on dialysis);
     • Chronic hepatic disease (cirrhosis, chronic viral hepatitis);
     • Metabolic disorders (diabetes mellitus types 1 and 2, thyroid disorders);
     • Neurologic and neurodevelopmental conditions (epilepsy, stroke, cerebral palsy, muscular dystrophy, spinal cord injury, cognitive impairment causing dysphagia or aspiration risk);
     • Immunocompromise (HIV/AIDS, hematologic malignancies, active chemotherapy, solid organ transplant recipients, daily chronic systemic corticosteroids [≥20 mg prednisone equivalent]);
     • Pregnancy and women within 2 weeks postpartum;
     • Severe obesity (Body Mass Index BMI ≥40 kg/m²);
     • Residents of nursing homes, assisted living facilities, and long-term care institutions;
     • American Indians and Alaska Natives.

---

Complications & Secondary Bacterial Pneumonia: The "Double Sickening" Phenomenon

While primary influenza viral pneumonia causes fulminant bilateral alveolar damage, the most common life-threatening pulmonary complication is secondary bacterial pneumonia.

The "Double Sickening" Trajectory

• Clinical Presentation: The patient develops typical influenza, experiences noticeable clinical improvement over days 2 to 4 (defervescence of fever, easing of myalgias), and then suddenly experiences an abrupt recrudescence on days 5 to 10 with new high-grade spiking fevers, violent shaking chills, worsening dyspnea, pleuritic chest pain, and productive cough with purulent, blood-tinged or rust-colored sputum.
• Pathophysiology: Influenza viral neuraminidase strips protective sialic acid residues from respiratory mucosal epithelial cells, denuding the tracheobronchial basement membrane, exposing fibronectin receptors, paralyzing mucociliary escalators, and inducing apoptosis of alveolar macrophages and neutrophils. This creates a primed microenvironment for secondary bacterial adherence and parenchymal invasion.

Microbial Pathogens & Antimicrobial Selection

1. Streptococcus pneumoniae: Most frequent causative organism overall (~50% of secondary bacterial pneumonias). Causes classical dense lobar consolidation, rusty sputum, and prominent leukocytosis with bandemia.
2. Staphylococcus aureus (MSSA and Community-Acquired MRSA): Particularly virulent and notorious following influenza. Often secretes the Panton-Valentine leukocidin (PVL) cytotoxin, causing severe necrotizing pneumonia, hemoptysis, multiple cavitary lung abscesses, pneumatoceles, empyema, profound leukopenia, and rapid progression to septic shock.
3. Group A Streptococcus (Streptococcus pyogenes): Causes rapidly progressive necrotizing pneumonia and massive, early-accumulating parapneumonic empyema.

• Empiric Inpatient Regimen: Requires immediate coverage for both S. pneumoniae and MRSA: Intravenous Ceftriaxone (1 to 2 g daily) PLUS Intravenous Vancomycin (15-20 mg/kg Q8-12H targeted to trough 15-20 mcg/mL or AUC 400-600) or Linezolid (600 mg IV Q12H).

---

Outpatient COVID-19 Management & Therapeutics

SARS-CoV-2 presentation spans asymptomatic infection to life-threatening acute respiratory distress syndrome (ARDS). In ambulatory care, risk stratification identifies individuals at high risk for progression to severe disease who benefit from early targeted antiviral therapeutics.

High-Risk Criteria for Severe COVID-19

• Age ≥65 years (the single strongest prognostic predictor of hospitalization and death);
• Unvaccinated or incompletely vaccinated status;
• Chronic kidney disease (especially stages 3-5);
• Chronic cardiopulmonary disease (COPD, moderate-to-severe asthma, heart failure, CAD);
• Diabetes mellitus (type 1 or type 2);
• Obesity (BMI ≥30 kg/m², with exponential risk at BMI ≥40 kg/m²);
• Moderate-to-severe immunocompromise (solid organ transplant, active malignancy, immunosuppressive therapies);
• Advanced liver disease, sickle cell disease, or neurodevelopmental disorders.

Outpatient Therapeutic Regimens

1. Nirmatrelvir-Ritonavir (Paxlovid) - Preferred First-Line Oral Therapy

• Mechanism: Nirmatrelvir is an orally active peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro / 3CLpro), blocking viral polyprotein cleavage. Ritonavir has no intrinsic anti-SARS-CoV-2 activity; it acts as a potent, irreversible CYP3A4 inhibitor (pharmacokinetic booster) that prevents the hepatic metabolism of nirmatrelvir, maintaining therapeutic plasma levels.
• Efficacy: Demonstrates an ~86% to 89% relative reduction in COVID-19-related hospitalization and death when initiated within 5 days of symptom onset.
• Standard Dosing: Nirmatrelvir 300 mg (two 150-mg pink tablets) PLUS Ritonavir 100 mg (one 100-mg white tablet) taken together orally twice daily for 5 days.
• Timing Window: Must be started within 5 days of symptom onset.
• Renal Dosage Adjustment:
  • eGFR ≥60 mL/min: Standard dose (300/100 mg PO BID);
  • eGFR 30 to 59 mL/min (moderate impairment): Reduce nirmatrelvir to 150 mg (one tablet) with ritonavir 100 mg (one tablet) PO BID for 5 days;
  • eGFR <30 mL/min or ESRD on dialysis: CONTRAINDICATED. Drug accumulation and safety data are lacking; alternative therapies (IV remdesivir) must be used.

Critical CYP3A4 Drug-Drug Interactions (Paxlovid)

Ritonavir profoundly inhibits CYP3A4, causing dangerous elevations of co-administered medications with narrow therapeutic indices:

• Statins: Simvastatin and lovastatin are absolutely contraindicated (severe rhabdomyolysis risk). Atorvastatin and rosuvastatin should be temporarily held during the 5-day treatment course and resumed 3 to 5 days after completion.
• Direct Oral Anticoagulants (DOACs): Rivaroxaban is absolutely contraindicated (dramatic elevation of drug levels and life-threatening hemorrhage). Apixaban levels increase significantly; consider temporary switch to enoxaparin/unfractionated heparin, or choose IV remdesivir.
• Antiarrhythmics: Amiodarone, flecainide, propafenone, dronedarone, quinidine are contraindicated due to fatal ventricular arrhythmias.
• Anticonvulsants: Carbamazepine, phenytoin, phenobarbital, and primidone are potent CYP inducers that drastically reduce nirmatrelvir/ritonavir plasma concentrations, causing viral therapeutic failure; combination is contraindicated.
• Immunosuppressants: Calcineurin inhibitors (tacrolimus, cyclosporine) and mTOR inhibitors (sirolimus, everolimus) experience marked, unpredictable level spikes causing acute renal shutdown and toxicity; requires specialized transplant team management or switching to remdesivir.
• Sedatives/Hypnotics: Midazolam, triazolam (prolonged sedation, respiratory depression).
• COVID-19 Rebound: A recurrence of mild symptoms or a new positive antigen test 2 to 8 days following completion of a 5-day course. Rebound is self-limited, does not progress to severe disease or hospitalization, and does not warrant a repeat course of Paxlovid.

2. Intravenous Remdesivir (Veklury) - Preferred Alternative

• Mechanism: Adenosine nucleotide analog that inhibits viral RNA-dependent RNA polymerase (RdRp), inducing premature chain termination.
• Regimen: 3-day outpatient intravenous infusion: 200 mg IV on Day 1, followed by 100 mg IV on Days 2 and 3.
• Timing Window: Initiated within 7 days of symptom onset (87% relative reduction in hospitalization).
• Clinical Indications: First-line alternative when Paxlovid is contraindicated due to severe renal failure (eGFR <30 mL/min), severe drug-drug interactions, or inability to swallow oral medication.

3. Molnupiravir (Lagevrio) - Secondary Oral Option

• Dosing: 800 mg (four 200-mg capsules) PO twice daily for 5 days, initiated within 5 days of onset.
• Efficacy: Modest efficacy (~30% relative reduction in hospitalization), significantly inferior to Paxlovid and Remdesivir. Reserved strictly for non-hospitalized adults when neither Paxlovid nor Remdesivir is clinically accessible.
• Contraindications: Strictly contraindicated in pregnancy (teratogenic, embryofetal lethality) and in patients aged <18 years (cartilage toxicity, bone growth plate malformations).

Explicitly Harmful / Non-Recommended Therapies in Outpatient COVID-19

• Systemic Corticosteroids (Dexamethasone): The landmark RECOVERY trial proved that dexamethasone reduces mortality in patients requiring supplemental oxygen or mechanical ventilation, but causes net harm (increased mortality and prolonged viral clearance) in patients who do NOT require supplemental oxygen! Never prescribe dexamethasone for ambulatory outpatients with SpO2 ≥94% on room air!
• Antibiotics (Azithromycin): Ineffective against viral infection; randomized trials demonstrate zero benefit while driving bacterial resistance.
• Ineffective Therapies: Hydroxychloroquine, ivermectin, colchicine, high-dose zinc, and vitamin C have failed to show benefit in randomized trials.

---

Respiratory Syncytial Virus (RSV) in Adults

RSV is increasingly recognized as a major pathogen in older adults (≥65 years) and individuals with chronic cardiopulmonary disorders (COPD, congestive heart failure, asthma) or severe immunocompromise, accounting for 60,000 to 160,000 hospitalizations annually in the United States.

• Clinical Presentation: Manifests as lower respiratory tract disease with persistent cough, wheezing, dyspnea, copious sputum production, and low-grade fever. It is a frequent precipitant of acute exacerbations of COPD (AECOPD) and acute decompensated heart failure (ADHF).
• Diagnostic Confirmation: Multiplex RT-PCR respiratory viral panel (nasopharyngeal swab).
• Management: Primarily supportive care: supplemental oxygen, judicious intravenous hydration, and inhaled short-acting bronchodilators (albuterol/ipratropium) for objective bronchospasm. Oral or inhaled ribavirin is reserved exclusively for select severely immunocompromised hosts (e.g., allogeneic hematopoietic cell transplant recipients) in specialty consultation.
• RSV Vaccines in Adults: Recombinant protein subunit vaccines (Arexvy, Abrysvo) and mRNA vaccines (mResvia) are recommended as a single lifetime dose for all adults aged ≥75 years, and for adults aged 60 to 74 years with chronic medical conditions (COPD, CHF, CKD, diabetes, immunocompromise) via shared clinical decision-making.